Evidence map›Paper›PMID 40604025›Full record

ArticleScientific reports2025

FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells.

Yuqing Feng, Philip Barbulescu, Chetan K Chana, Melika Shirdarreh, Hong Yang, Lizhen Wu, Sami Mamand, Mohammad Kashem, Amin Zia, Ming Han and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The many faces of the GID/CTLH E3 ligase complex.Biochemical Society transactions · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yuqing FengDepartment of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada. yqfeng@yorku.ca.
Philip BarbulescuDepartment of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
Chetan K ChanaLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, M5G 1X5, Canada.
Melika ShirdarrehDepartment of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
Hong YangJinan Vocational College of Nursing, Jinan, Shandong, China.
Lizhen WuDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Sami MamandDepartment of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
Mohammad KashemDepartment of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
Amin ZiadYcode Bio, Toronto, Canada.
Ming HanPrincess Margaret Cancer Centre, Toronto, Canada.
Julissa TsaoPrincess Margaret Cancer Centre, Toronto, Canada.
Trevor PughPrincess Margaret Cancer Centre, Toronto, Canada.
David CesconPrincess Margaret Cancer Centre, Toronto, Canada.
David G SchatzDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Frank SicheriLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, M5G 1X5, Canada.
Alberto MartinDepartment of Immunology, University of Toronto, Toronto, ON, M5S 1A8, Canada.
Rossanna C PezoSunnybrook Health Sciences Center, Toronto, ON, Canada. rossanna.pezo@sunnybrook.ca.

Funding

Targeting of somatic hypermutation in the genomeR01AI127642 · NIAID · YALE UNIVERSITY · PI SCHATZ, DAVID G. · 2017 to 2025
$4.6M
CIHR PJT-153307CIHR PJT-178026NIAID NIH HHS R01 AI127642NIH HHS R01-AI127642
6 · The paper itself

Abstract

Genetic lesions drive cancer development and progression, and understanding their origins will reveal the mechanisms of carcinogenesis. We showed that murine FAM72A promotes mutagenic DNA repair during antibody maturation by acting as a substrate adaptor of the CTLH

Indexed as

DNA GlycosylasesMutagenesisNeoplasmsAnimalsCell Line, TumorDNA RepairGene Expression Regulation, NeoplasticHumansMiceProteolysisDNA GlycosylasesBase excision repairCancerCytosine deaminationFAM72MutationUracil DNA glycosylase 2

Identifiers

PMID40604025
PMCPMC12223117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.